



(12) Translation of
European patent specification

(11) NO/EP 2732818 B1

NORWAY

(19) NO
(51) Int Cl.
A61K 31/422 (2006.01)
A61K 9/20 (2006.01)
A61P 9/12 (2006.01)
A61P 13/12 (2006.01)
C07D 413/12 (2006.01)

Norwegian Industrial Property Office


(21)	Translation Published	2017.10.16
(80)	Date of The European Patent Office Publication of the Granted Patent	2017.05.03
(86)	European Application Nr.	14155459.2
(86)	European Filing Date	2010.03.29
(87)	The European Application's Publication Date	2014.05.21
(30)	Priority	2009.03.31, US, 165419 P 2009.03.31, US, 165447 P
(84)	Designated Contracting States:	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR
(73)	Proprietor	Ligand Pharmaceuticals Inc., 3911 Sorrento Valley Boulevard Suite 110, San Diego, CA 92121, US-USA
(72)	Inventor	Zhang, Jinkun, 11496 Tree Hollow Lane, San Diego, CA California 92128, US-USA Dziewanowska, Zofia E, 765 Bonair Place, La Jolla, CA California 92037, US-USA Belder, Rene, 579 Province Line Road, Hopewell, NJ New Jersey 08525, US-USA Henderson, Ian, 5220 Fiore Terrace, No. 405, San Diego, CA California 92122, US-USA Bogardus, Joseph B, 892 Hurricane Road, Keene, NY New York 12942, US-USA Zhang, Zhaoying, 20 El Dorado Way, Monroe NJ 08831, US-USA

(54)	Title	A BIPHENYLSULFONAMIDE ENDOTHELIN AND ANGIOTENSIN II RECEPTOR ANTAGONIST TO TREAT GLOMERULOSCLEROSIS
(56)	References Cited:	WO-A1-00/01389 US-A1- 2002 143 024

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav


1. Sammensetning ifølge Formula I:



Formula I

5 eller et farmasøytisk akseptabelt salt derav for anvendelse i behandling av glomerulosklerose.

2. Anvendelse av en sammensetning ifølge Formula I:



Formula I

10 eller et farmasøytisk akseptabelt salt derav for fremstillingen av et medikament for behandlingen av glomerulosklerose.